← Eichor
Study identifier: NCT05739123 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring

Condition: Pregnancy Related · Pregnancy Complications · Pregnancy, High Risk  ·  Sponsor: Sumitomo Pharma Switzerland GmbH

PhaseN/A
Planned participants728
Who can joinFemale, 0 Years to no upper limit
Healthy volunteersNo

About this study

The Relugolix Pregnancy Registry is a prospective, observational cohort study designed to evaluate the association between relugolix-containing therapy exposure during pregnancy and subsequent maternal, fetal, and infant outcomes. Data will be collected from enrolled pregnant women and the healthcare providers (HCPs) involved in their care or the care of their infants, if applicable.

This description comes directly from the study's public registry record.

Talk to the study team

Clinical Trials at Myovant  ·  650-278-8743  ·  ClinicalTrials@Myovant.com

Myovant Medical Monitor Study Director

Always discuss trial participation with your own doctor first.

Locations (1)

PPDWilmington, North Carolina, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05739123